Millipore Home

• Home
• Products
• Services
• Learning Center
• Tech Library
• Support
• Company

Product Reference

Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.

Author	Päivi Lindholm, Merja H Voutilainen, Juha Laurén, Johan Peränen, Veli-Matti Leppänen, Jaan-Olle Andressoo, Maria Lindahl, Sanna Janhunen, Nisse Kalkkinen, Tõnis Timmusk, Raimo K Tuominen, Mart Saarma
Citation Information	Nature, 448:73-7 (2007)
Keywords	Amino Acid Sequence, Animals, Brain, Cloning, Molecular, Conserved Sequence, Corpus Striatum, Disease Models, Animal, Dopamine, Humans, In Situ Hybridization, Male, Mice, Molecular Sequence Data, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Neuroprotective Agents, Oxidopamine, Parkinson Disease, Protein Processing, Post-Translational, RNA, Messenger, Rats, Rats, Wistar, Substantia Nigra
Related Products	MAB318, MAB377
Pub Med ID	17611540

In Parkinson's disease, brain dopamine neurons degenerate most prominently in the substantia nigra. Neurotrophic factors promote survival, differentiation and maintenance of neurons in developing and adult vertebrate nervous system. The most potent neurotrophic factor for dopamine neurons described so far is the glial-cell-line-derived neurotrophic factor (GDNF). Here we have identified a conserved dopamine neurotrophic factor (CDNF) as a trophic factor for dopamine neurons. CDNF, together with its previously described vertebrate and invertebrate homologue the mesencephalic-astrocyte-derived neurotrophic factor, is a secreted protein with eight conserved cysteine residues, predicting a unique protein fold and defining a new, evolutionarily conserved protein family. CDNF (Armetl1) is expressed in several tissues of mouse and human, including the mouse embryonic and postnatal brain. In vivo, CDNF prevented the 6-hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons in a rat experimental model of Parkinson's disease. A single injection of CDNF before 6-OHDA delivery into the striatum significantly reduced amphetamine-induced ipsilateral turning behaviour and almost completely rescued dopaminergic tyrosine-hydroxylase-positive cells in the substantia nigra. When administered four weeks after 6-OHDA, intrastriatal injection of CDNF was able to restore the dopaminergic function and prevent the degeneration of dopaminergic neurons in substantia nigra. Thus, CDNF was at least as efficient as GDNF in both experimental settings. Our results suggest that CDNF might be beneficial for the treatment of Parkinson's disease.